While the big recent headlines in research regarding HIV and pregnancy have centered on the safety of dolutegravir (Tivicay), a number of new studies have advanced our knowledge in other areas. Most of the studies we've selected for this week's exploration highlight some of those not-just-about-dolutegravir pregnancy subjects. On tap in today's research run-through:
- Prior concerns regarding raltegravir (Isentress) use in pregnancy were overinflated, similar to prior concerns regarding dolutegravir use.
- There may be a relationship between a pregnant woman's comfort with disclosing her HIV status and her likelihood of achieving viral suppression.
- Any reductions in body size among newborns exposed to HIV appear to vanish within 18 months.
- Problems with hearing among people living with HIV (PLWH) appear to be related to the virus itself rather than the medications used to treat it.
Let's move in for a more detailed look. To beat HIV, you have to follow the science!